GT Biopharma (GTBP) EBITDA (2010 - 2026)

GT Biopharma (GTBP) has reported EBITDA for 17 consecutive years, with -$2.8 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, EBITDA fell 47.41% year-over-year to -$2.8 million in Q1 2026; TTM through Mar 2026 was -$13.3 million, a 1.01% decrease from a year earlier, with the FY2025 full-year figure at -$12.4 million, up 13.52% from the prior year.
• EBITDA was -$2.8 million for Q1 2026 at GT Biopharma, up from -$5.6 million in the prior quarter.
• Over five years, EBITDA peaked at -$1.5 million in Q2 2025 and troughed at -$7.0 million in Q3 2022.
• A 5-year average of -$3.8 million and a median of -$3.6 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA surged 81.24% in 2022 and sank 48.68% in 2025, its largest moves.
• Over 5 years, EBITDA stood at -$5.8 million in 2022, then surged by 45.17% to -$3.2 million in 2023, then declined by 18.78% to -$3.8 million in 2024, then tumbled by 48.68% to -$5.6 million in 2025, then soared by 49.1% to -$2.8 million in 2026.
• The last three EBITDA figures came in at -$2.8 million (Q1 2026), -$5.6 million (Q4 2025), and -$3.4 million (Q3 2025), per Business Quant data.